Quantum Biopharma (QNTM) Income towards Parent Company (2019 - 2026)

Quantum Biopharma has disclosed Income towards Parent Company across 8 years of filings, most recently posting -$13.6 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$13.6 million, down 58.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$30.7 million (down 74.14% YoY), and the FY2025 annual result was -$15.5 million, changed N/A from the prior year.
• Income towards Parent Company came in at -$13.6 million for Q1 2026 at Quantum Biopharma, down from -$2.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$444506.0 in Q1 2022 to a low of -$13.6 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$4.6 million (2024), against an average of -$5.3 million.
• Across the five-year window, Income towards Parent Company tumbled 2140.13% in 2023 and surged 80.89% in 2024, its largest moves.
• Quantum Biopharma's Income towards Parent Company stood at -$444506.0 in 2022, then tumbled by 1517.43% to -$7.2 million in 2023, then soared by 70.88% to -$2.1 million in 2024, then slipped by 20.93% to -$2.5 million in 2025, then slumped by 435.67% to -$13.6 million in 2026.
• The last three Income towards Parent Company figures came in at -$13.6 million (Q1 2026), -$2.5 million (Q4 2025), and -$5.3 million (Q3 2025), per Business Quant data.